Skip to content

The Greek experience with efalizumab in psoriasis from a university dermatologic hospital

The Greek experience with efalizumab in psoriasis from a university dermatologic hospital 1

C Antoniou, I Stefanaki, A Stratigos, G Avgerinou, P Stavropoulos, I Potouridou, D Polidorou, A E Moustou, M Kosmadaki, A D Katsambas (2007) The Greek experience with efalizumab in psoriasis from a University Dermatologic Hospital. Efalizumab-associated papular psoriasis is a common adverse event caused by efelizumab therapy. This clinical manifestation is characterized by a transient popular eruption localized especially on the flexural areas and on the back. The Greek experience with efalizumab in psoriasis from a University Dermatologic Hospital. Br J Dermatol. Efalizumab in Psoriasis Clinical Practice: Efalizumab Induction and Maintenance Therapy for Moderate to Severe Plaque-Type Psoriasis pp. Krasagakis, Kalliopi Psaroudaki, Androniki Tosca, Department of Dermatology, University Hospital of Heraklion, Crete, Greece.

The Greek experience with efalizumab in psoriasis from a university dermatologic hospital 2Research from JAMA Dermatology Systemic Therapy for Psoriasis and the Risk of Herpes Zoster A 500 000 Person-year Study. The Greek experience with efalizumab in psoriasis from a university dermatologic hospital. Br J Dermatol. The Greek experience with efalizumab in psoriasis from a university dermatologic hospital. PubMed journal article Efalizumab. Anti-CD11a monoclonal antibody–Genentech/Xoma, HU 1124, hu1124, xaneli was found in Unbound MEDLINE. Efalizumab. Anti-CD11a monoclonal antibody–Genentech/Xoma, HU 1124, hu1124, xanelim. The Greek experience with efalizumab in psoriasis from a University Dermatologic Hospital.

Those with more severe psoriasis experience similar levels of anxiety to patients with conditions such as breast cancer, osteoporosis, or metastatic prostate cancer 8, 9. All available biologic agents for the treatment of moderate to severe psoriasis in Greece, namely ustekinumab, etanercept, infliximab, and adalimumab, were included in the model as treatment options. CONCLUSIONS: Among the three agents, in the infliximab group a significant improvement in nail psoriasis was observed as early as week 14 of therapy whereas in the adalimumab and etanercept groups at week 24. Department of Dermatology, Psoriasis and Phototherapy Center, Hospital Universitari Sagrat Cor, Barcelona, Spain. CONCLUSIONS: Infliximab, in our experience, has proved to be effective in reducing nail lesions and, in some cases, even clearing them. University Hospitals of Cleveland (Case Western Reserve University) Dermatology, 1967-1970. Teaching Fellow, Department of Internal Medicine, 1970.

Jama Network

Greece; Dimitrios Rigopoulos, MD, PhD, Attikon General University Hospital,. Use of the Dermatology Life Quality Index (DLQI) in a midwestern US urban clinic on ResearchGate, the professional network for scientists. Article: The impact of acne Vulgaris on quality of life and psychic health in young adolescents in Greece. Biclonal gammopathy in a patient taking efalizumab for the treatment of psoriasis. Dr. Kofinas is also fluent in Greek. Very pleased with my experience and will be going back and referring others too. Efalizumab showed promising efficacy in the treatment of nail, scalp and palmoplantar psoriasis, which was reflected in improvements in quality of life. Patients who responded during the first-treatment period but experienced worsening psoriasis during the observation period could then receive further treatment with weekly open-label s. QoL was assessed at baseline and Weeks 2, 4, 8, 12 and 20 using the Dermatology Life Quality Index (DLQI) and the Medical Outcomes Study Short Form-36 (SF-36).

Budget Impact Analysis Of Ustekinumab In The Management Of Moderate To Severe Psoriasis In Greece